jRCT2080220475未知3 期
A randomized, double-blind, Phase II/III study of JR-013 in the patients with renal anemia receiving hemodialysis treatment
试验速览
- 阶段
- 3 期
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- A Randomized, Double-blind, Parallel Group Study
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •20 Years and above, Renal anemia patients receiving hemodialysis treatment
排除标准
- 未提供
结局指标
主要结局
-
Efficacy and Safety
次要结局
未报告次要终点
研究者
相似试验
未知
2 期
A randomized, double-blind, Phase II/III study of JR-013 in the patients with renal anemia receiving hemodialysis treatmentJPRN-jRCT2080220475KISSEI PHARMACEUTICAL CO.,LTD.
进行中（未招募）
1 期
A study of atezolizumab compared to placebo for subjects with late relapse ovarian cancer receiving a treatment with platinum-basedchemotherapy and bevacizumab.EUCTR2015-005471-24-FRARCAGY-GINECO405
进行中（未招募）
1 期
A study of atezolizumab compared to placebo for subjects with late relapse ovarian cancer receiving a treatment with platinum-basedchemotherapy and bevacizumab.Patients with late relapse of epithelial ovarien cancer, fallopian tube or peritoneal cancer treated with chemotherapy , bevacizumab and a anti PD-L1MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005471-24-BEARCAGY-GINECO600
进行中（未招募）
1 期
A study of atezolizumab compared to placebo for subjects with late relapse ovarian cancer receiving a treatment with platinum-based chemotherapy and bevacizumab.EUCTR2015-005471-24-ESARCAGY-GINECO405
进行中（未招募）
1 期
A study of atezolizumab compared to placebo for subjects with late relapse ovarian cancer receiving a treatment with platinum-based chemotherapy and bevacizumab.Patients with late relapse of epithelial ovarien cancer, fallopian tube or peritoneal cancer treated with chemotherapy , bevacizumab and a anti PD-L1MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005471-24-ATARCAGY-GINECO600